Understanding the Tailwind Behind Moderna Shares.

By Ken Smith • Thursday, December 14 17:35 • Permanent Link

This evening we watched Moderna rise 9.2% to a price of $85.87 per share. The large-cap Biotechnology company is now trading -28.41% below its average target price of $119.95. Analysts have set target prices ranging from $48.15 to $277.81 per share for Moderna, and have given the stock an average rating of hold.

Moderna has an average level of shares sold short, at 7.7% of its total share float. The stock's short ratio (also called days to cover) is 5.09. The company's insiders own 9.63% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 69.2% of Moderna's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Moderna

Date Reported	Holder	Percentage	Shares	Value
2023-09-30	Baillie Gifford and Company	12%	45,649,183	$3,919,895,469
2023-09-30	Vanguard Group Inc	7%	27,658,449	$2,375,031,091
2023-09-30	Blackrock Inc.	6%	24,739,386	$2,124,371,143
2023-09-30	State Street Corporation	4%	13,951,276	$1,197,996,108
2023-09-30	Flagship Pioneering Inc.	3%	9,666,038	$830,022,709
2023-09-30	Theleme Partners LLP	2%	6,897,612	$592,297,961
2023-09-30	Geode Capital Management, LLC	2%	6,415,009	$550,856,840
2023-09-30	Wellington Management Group, LLP	1%	5,611,119	$481,826,803
2023-09-30	Morgan Stanley	1%	5,312,014	$456,142,656
2023-09-30	Coatue Management LLC	1%	4,909,578	$421,585,476

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.